Metformin as an adjunct in T1D
Multiple generic manufacturers
What it is
An off-label adjunct with modest weight effects but no sustained glucose-control benefit in the large REMOVAL trial. It remains alongside insulin, with tolerability and patient selection limiting its role.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Glycemic benefit: REMOVAL found no sustained HbA1c improvement.[1]
- Important harms and treatment burden
- Safety: GI intolerance limits use; renal restrictions, boxed lactic-acidosis warning and vitaminB12 monitoring remain relevant.[2]
- Approval and country access
- US medicine labeling verified; T1D adjunct use is off-label. Other national availability and funding were not independently verified in this pass.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 25 × 25 + 55 × 25 + 40 × 15 + 75 × 20 + 40 × 15 = 4700; divide by total weight 100. Unrounded weighted result: 47.
GI intolerance limits use; renal restrictions, boxed lactic-acidosis warning and vitaminB12 monitoring remain relevant.[2]
These ratings concern add-on treatment alongside insulin in T1D. Maturity reflects the T1D evidence, and safety receives substantial editorial weight because risks differ by drug and population. For example, SGLT2 inhibitors can cause ketoacidosis even without markedly high glucose; this is not exclusive to T1D. Access reflects the stated indication and region, including whether a separate obesity indication applies.
Editor’s take
Scores are editorial judgments about the evidence and practical features, not measured comparative performance or a probability of success.
The full picture
REMOVAL randomized 428 adults aged 40+ with long-standing T1D and cardiovascular risk factors to metformin or placebo for three years. The primary mean carotid-wall-thickness outcome was not significantly improved. The early HbA1c reduction was not sustained; insulin dose was not reduced on average across three years.1
Weight was 1.17 kg lower versus placebo. Treatment discontinuation occurred in 27% versus 12%, mainly from gastrointestinal effects; hypoglycemia did not increase. These results do not establish prevention of heart attacks, a sustained glycemic benefit or a replacement for insulin.1
This is an off-label T1D evidence record, not a new approval. Local prescribing, renal suitability and medicine-label precautions require individual clinical assessment.
The label carries a boxed warning for lactic acidosis, contraindicates severe renal impairment and acute or chronic metabolic acidosis, and warns about vitaminB12 depletion. These are separate from REMOVAL’s tolerability results.2
Sources
- [1]REMOVAL randomized trial,428 adults · Peer-reviewed study
- [2]Current metformin label: renal restrictions, lactic acidosis and vitaminB12 · Regulatory decision
Current metformin prescribing information.